Compass Therapeutics, Inc.
CMPX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020–FY2025
Revenue
Total sales reported in the income statement.
$0.0M
100.0%
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$66.5M
Free cash flow
Cash from operations minus capital spending.
−$49.2M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What Compass Therapeutics, Inc. does
No business description yet.
- Legal name
- Compass Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Accession · CIK
- 0001171843-26-001337
0001738021
Revenue and margins
Compass Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
FY20
Revenue —
FY21
Revenue —
FY22
Revenue —
FY23
Revenue $0.0M
FY24
Revenue $0.9M
FY25
Revenue $0.0M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue —
Q2 '24
Revenue $0.9M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue —
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue —
Q2 '26
Revenue —
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating −6,661.8%
Net −5,808.8%
FCF −5,282.2%
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Q3 '23
Gross —
Operating —
Net —
FCF —
Q4 '23
Gross —
Operating —
Net —
FCF —
Q1 '24
Gross —
Operating —
Net —
FCF —
Q2 '24
Gross —
Operating −1,770.0%
Net −1,538.4%
FCF −1,265.2%
Q3 '24
Gross —
Operating —
Net —
FCF —
Q4 '24
Gross —
Operating —
Net —
FCF —
Q1 '25
Gross —
Operating —
Net —
FCF —
Q2 '25
Gross —
Operating —
Net —
FCF —
Q3 '25
Gross —
Operating —
Net —
FCF —
Q4 '25
Gross —
Operating —
Net —
FCF —
Q1 '26
Gross —
Operating —
Net —
FCF —
Q2 '26
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income −$29.5M
FY21
Net income −$82.2M
FY22
Net income −$39.2M
FY23
Net income −$42.5M
FY24
Net income −$49.4M
FY25
Net income −$66.5M
Q3 '23
Net income −$10.0M
Q4 '23
Net income −$13.4M
Q1 '24
Net income −$10.8M
Q2 '24
Net income −$13.1M
Q3 '24
Net income −$10.5M
Q4 '24
Net income −$15.0M
Q1 '25
Net income −$16.6M
Q2 '25
Net income −$19.9M
Q3 '25
Net income −$14.3M
Q4 '25
Net income −$15.7M
Q1 '26
Net income −$18.3M
Q2 '26
Net income −$25.2M
FY20
Diluted EPS −$0.96
FY21
Diluted EPS −$1.31
FY22
Diluted EPS —
FY23
Diluted EPS —
FY24
Diluted EPS —
FY25
Diluted EPS —
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital −997.3%
Return on equity −73.9%
Return on assets −56.8%
FY21
Return on capital —
Return on equity −91.3%
Return on assets −79.9%
FY22
Return on capital —
Return on equity −24.4%
Return on assets −22.2%
FY23
Return on capital —
Return on equity −25.7%
Return on assets −23.8%
FY24
Return on capital —
Return on equity −36.1%
Return on assets −33.2%
FY25
Return on capital —
Return on equity −41.3%
Return on assets −36.9%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$49.2M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY20
Free cash flow −$26.9M
FY21
Free cash flow −$21.2M
FY22
Free cash flow −$34.3M
FY23
Free cash flow −$40.6M
FY24
Free cash flow −$44.9M
FY25
Free cash flow −$49.2M
Q3 '23
Free cash flow −$5.9M
Q4 '23
Free cash flow −$12.4M
Q1 '24
Free cash flow −$13.9M
Q2 '24
Free cash flow −$10.8M
Q3 '24
Free cash flow −$11.1M
Q4 '24
Free cash flow −$9.2M
Q1 '25
Free cash flow −$13.2M
Q2 '25
Free cash flow −$11.8M
Q3 '25
Free cash flow −$10.9M
Q4 '25
Free cash flow −$13.3M
Q1 '26
Free cash flow −$17.4M
Q2 '26
Free cash flow −$14.9M
FY20
Cash from operations −$26.8M
Capital spending $0.1M
FY21
Cash from operations −$19.7M
Capital spending $1.6M
FY22
Cash from operations −$34.1M
Capital spending $0.2M
FY23
Cash from operations −$40.6M
Capital spending $0.0M
FY24
Cash from operations −$44.9M
Capital spending $0.0M
FY25
Cash from operations −$49.1M
Capital spending $0.0M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$5.9M
Capital spending $0.0M
Q4 '23
Cash from operations −$12.4M
Capital spending $0.0M
Q1 '24
Cash from operations −$13.9M
Capital spending $0.0M
Q2 '24
Cash from operations −$10.8M
Capital spending $0.0M
Q3 '24
Cash from operations −$11.1M
Capital spending $0.0M
Q4 '24
Cash from operations −$9.2M
Capital spending $0.0M
Q1 '25
Cash from operations −$13.2M
Capital spending $0.0M
Q2 '25
Cash from operations −$11.8M
Capital spending $0.0M
Q3 '25
Cash from operations −$10.8M
Capital spending $0.0M
Q4 '25
Cash from operations −$13.3M
Capital spending $0.0M
Q1 '26
Cash from operations −$17.3M
Capital spending $0.1M
Q2 '26
Cash from operations −$14.7M
Capital spending $0.2M
Cash from operations
Capital spending
Dividends, buybacks and share count
Compass Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY20
Diluted shares 0.03B
FY21
Diluted shares 0.06B
FY22
Diluted shares —
FY23
Diluted shares —
FY24
Diluted shares 0.14B
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Compass Therapeutics, Inc. can carry it.
FY20
Cash $47.1M
Debt $9.3M
FY21
Cash $145M
Debt $0.0M
FY22
Cash $187M
Debt —
FY23
Cash $152M
Debt —
FY24
Cash $127M
Debt —
FY25
Cash $209M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $145M | $187M | $152M | $127M | $209M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Debt / equity | 0.0x | — | — | — | — |
| Interest coverage | −221.3x | — | — | — | — |
| Current ratio | 13.8x | 12.0x | 19.7x | 15.0x | 15.0x |
| Quick ratio | 13.8x | 12.0x | 19.7x | 15.0x | 15.0x |
| Total assets | $154M | $200M | $157M | $140M | $220M |
| Total liabilities | $13.7M | $18.0M | $8.3M | $15.2M | $22.8M |
| Shareholders' equity | $140M | $182M | $149M | $125M | $197M |
| Net debt (− = net cash) | −$145M | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✓ | — | — | — | — |
| Current ratio rose | — | ✓ | ✕ | ✓ | ✕ | ✓ |
| Share count didn't rise | — | ✕ | — | — | — | — |
| Gross margin rose | — | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | ✓ | ✕ |
| F-score | — / 3 | 4 / 7 | — / 5 | — / 5 | — / 6 | — / 6 |
| Accruals ratio | −5.2% | −60.8% | −2.9% | −1.1% | −3.0% | −9.6% |
| Altman Z'' | −4.54 | 8.04 | 10.60 | 16.11 | 3.28 | 6.28 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | $0.0M | $0.9M | $0.0M |
| Research and development | $14.9M | $20.3M | $30.0M | $38.1M | $42.3M | $56.0M |
| Operating income | −$27.8M | −$81.9M | −$41.7M | −$50.4M | −$56.6M | −$72.8M |
| Interest expense | $0.9M | $0.4M | $0.0M | — | — | — |
| Pretax income | −$29.5M | −$82.2M | −$39.2M | −$42.5M | — | — |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$29.5M | −$82.2M | −$39.2M | −$42.5M | −$49.4M | −$66.5M |
| Diluted EPS | −$0.96 | −$1.31 | — | — | — | — |
| Diluted shares | 0.03B | 0.06B | — | — | 0.14B | — |
| Cash flow | ||||||
| Cash from operations | −$26.8M | −$19.7M | −$34.1M | −$40.6M | −$44.9M | −$49.1M |
| Capital expenditure | $0.1M | $1.6M | $0.2M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$26.9M | −$21.2M | −$34.3M | −$40.6M | −$44.9M | −$49.2M |
| Depreciation and amortization | $2.4M | $0.6M | $0.8M | $0.7M | $0.6M | $0.3M |
| Stock-based compensation | $4.0M | $4.0M | $5.3M | $6.1M | $8.6M | $8.4M |
| Acquisitions | — | $0.3M | $0.0M | — | — | — |
| Balance sheet | ||||||
| Cash and short-term investments | $47.1M | $145M | $187M | $152M | $127M | $209M |
| Total debt | $9.3M | $0.0M | — | — | — | — |
| Current assets | $50.2M | $147M | $195M | $154M | $133M | $210M |
| Current liabilities | $10.1M | $10.6M | $16.2M | $7.8M | $8.9M | $14.0M |
| Property and equipment, net | $1.1M | $2.2M | $1.6M | $0.9M | $0.4M | $0.1M |
| Total assets | $51.9M | $154M | $200M | $157M | $140M | $220M |
| Total liabilities | $12.0M | $13.7M | $18.0M | $8.3M | $15.2M | $22.8M |
| Preferred stock | $0.0M | $0.0M | — | — | — | — |
| Shareholders' equity | $39.9M | $140M | $182M | $149M | $125M | $197M |
| Margins | ||||||
| Operating margin | — | — | — | — | −6,661.8% | — |
| EBITDA margin | — | — | — | — | −6,592.5% | — |
| Net margin | — | — | — | — | −5,808.8% | — |
| FCF margin | — | — | — | — | −5,282.2% | — |
| Returns | ||||||
| Return on capital | −997.3% | — | — | — | — | — |
| Return on capital employed | −66.5% | −57.2% | −22.7% | −33.8% | −43.1% | −35.4% |
| Return on equity | −73.9% | −91.3% | −24.4% | −25.7% | −36.1% | −41.3% |
| Return on assets | −56.8% | −79.9% | −22.2% | −23.8% | −33.2% | −36.9% |
| Return on tangible equity | −73.9% | −58.7% | −21.6% | −28.6% | −39.4% | −33.8% |
| Growth | ||||||
| Revenue growth | — | — | — | — | — | −100.0% |
| Share count change | — | 104.3% | — | — | — | — |
| Financial health | ||||||
| Debt / equity | 0.2x | 0.0x | — | — | — | — |
| Interest coverage | −30.6x | −221.3x | — | — | — | — |
| Current ratio | 5.0x | 13.8x | 12.0x | 19.7x | 15.0x | 15.0x |
| Quick ratio | 5.0x | 13.8x | 12.0x | 19.7x | 15.0x | 15.0x |
| Capital allocation | ||||||
| Capex / revenue | — | — | — | — | 5.2% | — |
| Stock comp / revenue | — | — | — | — | 1,007.1% | — |
| Quality scores | ||||||
| Piotroski F-score | — | 4.0 | — | — | — | — |
| Altman Z'' | −4.5 | 8.0 | 10.6 | 16.1 | 3.3 | 6.3 |
| Accruals ratio | −5.2% | −60.8% | −2.9% | −1.1% | −3.0% | −9.6% |
Source: SEC EDGAR XBRL filings (CIK 0001738021). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.